Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Study of AMG 673 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03224819
Recruitment Status : Terminated (Priortization of other programs)
First Posted : July 21, 2017
Last Update Posted : March 18, 2022
Information provided by (Responsible Party):

Brief Summary:
This is a first-in-human, open-label, phase 1, sequential dose escalation study. AMG 673 will be evaluated as a short term intravenous (IV) infusion in adult subjects with relapsed/refractory AML. The study will be conducted at approximately 7 sites in the United States, Australia and Germany.

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Drug: AMG 673 Early Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 46 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Intervention Model Description: Bayesian Model
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 673 Administered as Short Term Intravenous Infusions in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Actual Study Start Date : September 7, 2017
Actual Primary Completion Date : December 28, 2020
Actual Study Completion Date : December 28, 2020

Arm Intervention/treatment
Experimental: Exploration Phase
Dose finding phase of the study
Drug: AMG 673
Open label.

Experimental: Expansion Phase
Maximum Tolerated Dose identified by Exploration Phase administered to subjects
Drug: AMG 673
Open label.

Primary Outcome Measures :
  1. Subject incidence and grade of adverse events [ Time Frame: 18 months ]
  2. Dose limiting toxicities (DLTs) [ Time Frame: 18 Months ]

Secondary Outcome Measures :
  1. Pharmacokinetic parameter - half-life [ Time Frame: 18 months ]
  2. Pharmacokinetic parameter - steady state [ Time Frame: 18 months ]
  3. Pharmacokinetic parameter - Concentration [ Time Frame: 18 months ]
  4. Pharmacokinetic parameter - Volume of distribution [ Time Frame: 18 months ]
  5. Pharmacokinetic parameter - Clearance of AMG 673 [ Time Frame: 18 months ]
  6. Efficacy parameters - response rate [ Time Frame: 18 months ]
  7. Efficacy parameters - duration of response [ Time Frame: 18 months ]
  8. Efficacy parameters - time to progression [ Time Frame: 18 months ]
  9. Efficacy parameters - time to response [ Time Frame: 18 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Subject has provided informed consent prior to initiation of any study-specific activities/procedures.
  • Subjects ≥ 18 years of age at the time of signing consent.
  • AML as defined by the WHO Classification (Appendix D) persisting or recurring following 1 or more treatment courses except promyelocytic leukemia (APML).

More than 5% myeloblasts in bone marrow.

-Eastern Cooperative Oncology Group (ECOG, Appendix F) Performance Status of ≤ 2.

Exclusion Criteria

  • Known hypersensitivity to immunoglobulins.
  • Autologous HSCT within 6 weeks prior to start of AMG 673 treatment.
  • Allogeneic HSCT within 3 months prior to start of AMG 673 treatment.
  • Non-manageable graft versus host disease.
  • Known positive test for human immunodeficiency virus (HIV).
  • Males and females of reproductive potential who are unwilling to practice a highly effective method(s) of birth control while on study through 15 weeks after receiving the last dose of study drug. Acceptable methods of highly effective birth control include sexual abstinence (males, females); vasectomy; bilateral tubal ligation/occlusion; or a condom with spermicide (men) in combination with hormonal birth control or intrauterine device (IUD) (women). Males who are unwilling to abstain from sperm donation while on study through 5 half-lives after receiving the (last [multiple-dose studies]) dose of study drug.
  • Females who are lactating/breastfeeding or who plan to breastfeed while on study through 15 weeks after receiving the last dose of study drug.
  • Females with a positive pregnancy test
  • Females planning to become pregnant while on study through 15 weeks after receiving the last dose of study drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03224819

Layout table for location information
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
United States, California
City of Hope National Medical Center
Duarte, California, United States, 91010
United States, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Washington
University of Washington
Seattle, Washington, United States, 98109
Australia, Victoria
The Alfred Hospital
Melbourne, Victoria, Australia, 3004
The Royal Melbourne Hospital
Parkville, Victoria, Australia, 3050
Klinikum der Ludwig Maximilians Univeritaet
München, Germany, 81377
Sponsors and Collaborators
Layout table for investigator information
Study Director: MD Amgen
Additional Information:
Layout table for additonal information
Responsible Party: Amgen Identifier: NCT03224819    
Other Study ID Numbers: 20160377
First Posted: July 21, 2017    Key Record Dates
Last Update Posted: March 18, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access Criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type